Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.
Moshe Yair LevyLisa J McGarryHui HuangStephanie LustgartenSilvia ChiroliSergio IannazzoPublished in: Current medical research and opinion (2018)
Based on these surrogate measures of patient benefit-risk profiles, ponatinib appears to provide a net overall benefit vs. bosutinib in 3L CP-CML.